HIV / AIDS

When the CD4 count seems too good to be true.

A study suggests young black MSM can experience delays in PrEP initiation if they do not have health insurance, even if expanded access through manufacturer assistance programs is offered.

The study focused on women living with HIV in areas where TB is highly prevalent.

Investigators with The University of Texas Health Science Center embarked on a study to determine whether HIV disclosure at the emergency department should be based on preliminary results.

Patients with a new diagnosis of HIV may benefit from rapid start of ART.

Anandi Sheth, MD, MSc, summarizes her presentation on HIV prevention in women and discusses the need for more women in pre-exposure prophylaxis research.

Jason Schafer, PharmD, MPH, BCPS AQ-ID, previews the October issue featuring an article on rapid initiation of antiretroviral therapy.

HIV testing rates have improved among men who have sex with men in Africa, but new research indicates the developments are not enough to meet the UNAID’s 90-90-90 targets.

University of Illinois at Chicago investigators compared virologic failure among MSM and transgender women receiving HIV care at a community-based model with those receiving care at a hospital-based model.

For individuals living with HIV, switching suppressive HIV regimens may be considered for a variety of reasons including treatment simplification, improved safety and tolerability, drug-drug interactions, or cost.

ART-related medication errors can occur and lead to suboptimal therapy and in some cases treatment resistance.

Approximately ≥60% of men who have sex with men (MSM) find sexual partners via the internet, primarily through Grindr, which is the most popular dating app among MSM.

In general, women shared many of the same positive perceptions of long-acting ART that men did but offered unique insight.

Switching from TDF to TAF was associated with a 13% increase in the expected mean for ASCVD risk score (95% CI: 4%, 23%).

The study investigators conclude that U=U awareness seems to be improving among GBMSM, with HIV-negative individuals making the most progress.

The mobile unit provided services to 229 clients from October 2018 to April 2019, 168 (73.7%) of whom sought PrEP.

The risk of incident DM was more substantial with INSTIs vs. NNRTIs (HR=1.22; CI: 0.95-1.57), and a similar rate was noted with PI- vs. NNRTI-initiators (HR=1.25; CI: 1.05-1.49).

A 7-year study highlights the ability of an ultra-long-acting injectable implant to elute HIV drug combinations for months at a time.

In order to overcome the barriers to HIV care, it is important for both patients and health care professionals to mutually agree that a particular strategy is useful.

The FDA has approved a pre-exposure prophylaxis (PrEP) indication for Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets; F/TAF).

Microarray patches could be key to providing a self-delivery system, that is also discreet, to administer HIV prevention and contraception to women in low-resource settings.

Awareness for HIV PrEP was high for all racial and ethnic groups, but black and Hispanic MSM discussed its use with physicians less often than white counterparts.

As September draws to a close, the Contagion® editorial team is recapping the trends and top infectious disease news of the month.

STI rates have been growing significantly in the United States and around the world. To fix the problem, we need a renewed focus on this therapeutic area, according to top public health officials.

According to results from the Rwanda Population-based HIV Impact Assessment (RPHIA), 76% of all adults living with HIV in Rwanda have achieved viral load suppression.

Investigators used national electronic health record data to determine the proportion of American adults who have been tested for HIV.

Amid growing reports of viral resistance in patients living with HIV, IDSA, HIV Medicine Association, and American Academy of HIV Medicine have issued a joint policy paper.

Jump-starting HIV treatment in hospital emergency department settings could be a key to curbing the spread of the virus.

The approval allows treatment-experienced adults living with HIV who are virally suppressed to switch to doravirine or doravirine/lamivudine/tenofovir disoproxil fumarate.

Along with other heart ailments, new research finds that people living with HIV have a greater risk of atrial fibrillation.